Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dimitrios Bliagos

Interventional Cardiology White Plains, NY Medical Doctor

NPI 1013164201 CMS profile 182117

33 Davis Avenue, White Plains, NY 10605

Open in the dashboard

General payments

$61,647

435 records reported · program years 2019–2025

Research payments

$319

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dimitrios Bliagos of White Plains, NY is reported in the CMS Open Payments database as having received $61,647 across 435 general payments and $319 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $22,967 82
2024 General $9,936 40
2023 General $12,062 37
2023 Research $319 5
2022 General $2,648 53
2021 General $9,340 62
2020 General $1,647 75
2019 General $3,047 86

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dimitrios Bliagos
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Dimitrios Bliagos were reported at $22,967. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Dimitrios Bliagos Interventional Cardiology median Middle half National median
2019 $3,047 $1,097 $329–$3,048 $163
2020 $1,647 $473 $161–$1,480 $114
2021 $9,340 $677 $233–$1,827 $132
2022 $2,648 $978 $333–$2,724 $149
2023 $12,062 $1,136 $382–$2,986 $160
2024 $9,936 $1,181 $395–$3,326 $164
2025 $22,967 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $24,063 110 payments
  2. Shockwave Medical, Inc $10,972 13 payments
  3. Medtronic, Inc. $10,183 72 payments
  4. Magenta Medical Inc $5,632 3 payments
  5. Abiomed $5,365 79 payments
  6. Abbott Laboratories $1,568 39 payments
  7. Medtronic Vascular, Inc. $734 28 payments
  8. Cardiovascular Systems Inc. $503 28 payments
  9. Asahi Intecc USA, Inc. $484 12 payments
  10. Edwards Lifesciences Corporation $354 3 payments
  11. Other $1,789 48 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $26,953 6 payments
  2. Food and Beverage $15,736 405 payments
  3. Consulting Fee $13,900 5 payments
  4. Travel and Lodging $5,059 19 payments
Products named General payments · program years 2019–2025
  1. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $10,556 8 payments
  2. Resolute $7,986 11 payments
  3. Impella $5,083 74 payments
  4. General - Vascular Access $4,000 1 payment
  5. AVVIGO Guidance System $2,081 34 payments
  6. Coronary Orbital Atherectomy System $470 24 payments
  7. SYMPLICITY G3 $463 8 payments
  8. Optis Coronary Imaging System $442 11 payments
  9. Asahi Coronary Wires $437 9 payments
  10. Xience Sierra Coronary Stent $411 15 payments
  11. Other $8,362 233 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Abiomed $319 5 payments

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

14

Median for Interventional Cardiology: 2,236

Drug cost

$40

Median for Interventional Cardiology: $380,412

Branded share of claims

100%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 14 $40

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$170,453

Medicare's payments for the services billed

Medicare patients

996

Average age 77

Services billed

2,009

478 women, 518 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 70%
Arthritis 62%
Chronic kidney disease 55%
Diabetes 51%
Heart failure 48%
Atrial fibrillation 44%
COPD 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $27
  • PFIZER INC. $22
$48 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $28
$28 — —
PAXLOVID
  • PFIZER INC. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

440 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record